The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD ...

Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing tool Crispr (Alamy/PA) Ella Pickover6 days ago A £1.65 million treatment has been approved for use for ...

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK ... and potentially expanding its label. Multiple trials are exploring ...

40,997 people played the daily Crossword recently. Can you solve it faster than others?40,997 people played the daily Crossword recently. Can you solve it faster than others? New bird flu variant ...

Notably, 93% of the company’s total sales are generated by Trikafta/Kaftrio. Vertex’s Casgevy – a CRISPR gene-edited cell therapy for the treatment of sickle cell disease and beta ...

Doudna, the Nobel Prize in Chemistry in 2020. Exa-cel, also called Casgevy, involves taking a person’s blood stem cells, using CRISPR to edit them in a lab, and replacing them in the patient.

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, ...

It is believed around 1,700 people could be eligible after the National Institute for Health and Care Excellence (Nice) approved Casgevy for some patients with the genetic condition. Around 50 ...